Absci to Report Business Updates and First Quarter 2026 Financial and Operating Results on May 7, 2026
Absci (Nasdaq: ABSI) will report business updates and first quarter 2026 financial and operating results after market close on May 7, 2026.
Rhea-AI Summary
Absci (Nasdaq: ABSI) will report business updates and first quarter 2026 financial and operating results after market close on May 7, 2026. Management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT. Live audio and a replay will be available on the company investor relations website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – ABSI
In the Apr 24 session, ABSI declined 0.76%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- 2025 Revenue
- $2.8 million
- Full-year 2025; down from $4.5 million in 2024
- 2024 Revenue
- $4.5 million
- Full-year 2024 partner program revenue baseline
- 2025 R&D Expense
- $81.4 million
- Full-year 2025; up from $63.9 million in 2024
- 2025 Net Loss
- $115.2 million
- Full-year 2025; wider than $103.1 million in 2024
- Cash & Securities
- $144.3 million
- As of December 31, 2025; company cites runway into 1H 2028
- Shelf Capacity
- $400,000,000
- Preliminary Form S-3 shelf filed August 12, 2025
- Non-affiliate Equity Value
- $303.8 million
- Aggregate market value as of June 30, 2025
- Shares Outstanding
- 153,021,263
- Common shares outstanding as of March 6, 2026
Previous Earnings date Reports
-
Set date and webcast details for Q4 and full-year 2025 results.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
generative AI technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
VANCOUVER, Wash. and NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the first quarter 2026 after market close on Thursday, May 7, 2026.
Absci management will webcast a corresponding conference call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss its business developments, financial and operating results, and outlook.
Live audio of the webcast will be available on the company’s investor relations website at: investors.absci.com. The webcast will be archived and available for replay after the event.
About Absci
Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201™, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential “best-in-class” therapeutic for endometriosis, a condition with significant unmet medical need and market potential. Absci is headquartered in Vancouver, WA, with AI Research Labs in New York City and Serbia, and an Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.
Absci® standard character mark, ABS-201™, and Integrated Drug Creation™ are trademarks and registered trademarks of Absci Corporation.
Investor Contact
Alexander D.H. Khan
Corporate Vice President, Head of Investor Relations
investors@absci.com
Media Contact
press@absci.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.